A new COVID-19 medication has been approved in Abu Dhabi for the treatment of mild to moderate cases and those who have had direct contact with a patient.
The emirate's Department of Health (DoH) has partnered with Swiss healthcare company Roche to provide casirivimab and imdevimab to certain categories of patients.
The antibody combination has already been approved in the European Union and Japan, and conditionally approved in the UK and Australia.
It is also authorised for emergency use in the United States, India, Switzerland and Canada, and is recommended by the World Health Organisation (WHO).
.@DoHSocial has partnered with Swiss healthcare company @Roche to provide a new Covid-19 medication, approved for emergency use, to treat mild to moderate Covid-19 cases and those who have had direct contact with a positive case.
— مكتب أبوظبي الإعلامي (@ADMediaOffice) December 1, 2021
Read more: https://t.co/vGQXyUvhGB pic.twitter.com/Yj9JxVgemP


Salik to apply peak-hour toll rates for Dubai Ride
Mattar Al Tayer named Chairman of MBR Endowment District Board
Sheikh Khaled calls for integrated global economic system at APEC
UAE launches aid mission for hurricane-hit Caribbean nations
New paid parking zones introduced in Dubai
H.H. Sheikh Khaled holds talks with South Korean President
UAE fuel prices to drop in November
Abu Dhabi Crown Prince arrives in South Korea for APEC Forum
